JARID1B promotes colorectal cancer proliferation and Wnt/β-catenin signaling via decreasing CDX2 level

Da Huang
Nanchang University Second Affiliated Hospital

Fan Xiao
Nanchang University Second Affiliated Hospital

Haibin Hao
Nanchang University Second Affiliated Hospital

Fuzhou Hua
Nanchang University Second Affiliated Hospital

Zhenzhong Luo
Nanchang University Second Affiliated Hospital

Zhaoxia Huang
Nanchang University Second Affiliated Hospital

Qing Li
Nanchang University Second Affiliated Hospital

Sha Chen
Nanchang University Second Affiliated Hospital

Xiuzhi Cheng
Nanchang University Second Affiliated Hospital

Xinyue Zhang
Nanchang University Second Affiliated Hospital

Weilan Fang
Nanchang University Second Affiliated Hospital

Xiaoyun Hu
Nanchang University Second Affiliated Hospital

Fanrong Liu (fanrongliu123@163.com)
Nanchang University Second Affiliated Hospital

https://orcid.org/0000-0002-9783-492X

Research

Keywords: colorectal cancer, cell proliferation, JARID1B, CDX2, H3K4me3, Wnt/β-catenin
Abstract

**Background:** Jumonji AT-rich interactive domain 1B (JARID1B) has been shown to be upregulated in many human cancers and plays a critical role in the development of cancers cells. Nevertheless, its functional role in colorectal cancer (CRC) progression is not fully understood.

**Methods:** Herein, JARID1B expression levels were detected in clinical CRC samples by western blotting and qRT-PCR. DLD-1 cells with JARID1B knockdown or overexpression by stably transfected plasmids were used in vitro and in vivo study. Colony formation, 5-ethynyl-20-deoxyuridine (EdU) and Real Time Cellular Analysis (RTCA) assays were used to detect cell proliferation and growth. Transcriptome and CHIP assays were used to examine the molecular biology changes and molecular interaction in these cells. Nude mice was utilized to study the correlation of JARID1B and tumor growth in vivo.

**Results:** Here, we first observed that JARID1B was significantly upregulated in CRC tissue compared to adjacent normal tissues. In CRC patients, JARID1B high expression was positively relation with poor overall survival. Multivariate analyses revealed that high JARID1B expression was an independent predictive marker for the poor prognosis of CRC. In addition, we found that JARID1B promoted CRC cells proliferation by Wnt/β-catenin signaling pathway. Further studies demonstrated CDX2 as a downstream target of JARID1B, and our data demonstrated that CDX2 is crucial for JARID1B -mediated Wnt/β-catenin signaling pathway. Mechanistically, we demonstrated that JARID1B regulated CDX2 expression through demethylation of H3K4me3.

**Conclusions:** CDX2 inhibited by JARID1B-derived H3K4me3 methylation promoted cells proliferation of CRC via Wnt/β-catenin signaling pathway. Therefore, our studies provided a novel insight into the role of JARID1B in CRC cells proliferation and potential new molecular target for treating CRC.

**Background**

Colorectal cancer (CRC) is the most common cancer with high morbidity worldwide and is the third leading cause of cancer-related death in men and the second leading cause in women[1, 2]. In recent decades, although diagnosis and treatment techniques have improved and new cancer therapeutics, including molecular targeted therapies and immunotherapies, have occurred, cancer prognosis is still unsatisfactory because of the dysregulation of cell death and proliferation mechanisms in cancer[3, 4]. Because the cell proliferation and metastasis of CRC are the most common causes of death, exploring the molecular mechanism of CRC cell proliferation is a vital issue in the treatment of CRC[5]. Moreover, epigenetic regulation of gene expression has been shown to provide new insights into the pathogenesis of CRC[6]. In particular, methylation and demethylation of histone lysine residues act as transcriptional switches for gene expression under physiological and disease conditions[7]. In this study, we showed that a new target related to histone methylation modification can regulate CRC cell proliferation.

JARID1 proteins are histone demethylases that regulate the fate of normal cells and contribute to malignant transformation[8]. The JARID1 family members include JARID1A, JARID1B, JARID1C and
JARID1D[9, 10]. JARID1B (also known as KDM5B) has been studied mostly so far. JARID1B was originally considered a transcription inhibitor to regulate the cell cycle, cell differentiation and cell proliferation[11]. JARID1B can specifically remove H3K4 trimethylation and inhibit relative gene transcription[12]. Recently, there has been an increasing number of studies on JARID1B in malignant tumours. JARID1B is an oncogenic epigenetic factor overexpressed in different types of cancers, such as breast cancer, lung cancer, prostate cancer, osteosarcoma, oral cancers, melanoma, glioma, hepatocellular carcinoma, gastric cancer and pancreatic cancer[13, 14]. The depletion of JARID1B has been shown to specifically inhibit H3K4 demethylation and suppress CRC cell growth[15]. Nevertheless, the clinical significance of JARID1B expression levels in CRC clinical samples has not been studied in detail, and its specific mechanism of action in the process of CRC progression is still unclear.

The Wnt family consists of 19 secretory cysteine-rich glycoproteins that all play principal regulatory roles in many developmental and biological processes, such as cell fate specification, proliferation, migration and asymmetric cell division[16]. Furthermore, Wnt/β-catenin signalling plays important roles in tissue maintenance and regeneration[17]. Recently, emerging evidence links the biological function of Wnt/β-catenin signalling to tumorigenesis and development[18]. At present, the molecular mechanism of tumorigenesis and development related to the activation of Wnt signalling, which increases β-catenin levels, represents a common pathway in Wnt signalling activation, that is, to enhance the translocation of β-catenin into cell nuclei where it binds to transcription factors of the TCF/LEF family. The β-catenin-TCF/LEF complex then induces transcription of downstream target genes in cancer, such as c-MYC and cyclin D1[19]. Recent studies have demonstrated that abnormal activation of Wnt/β-catenin signalling has often been reported in colorectal cancer (CRC). For example, activation of the Wnt signalling pathway is required for tumour growth in advanced CRC, and activation of Wnt signalling to β-catenin contributes to the development of CRC [20, 21]. However, the regulatory mechanisms of abnormal activation of Wnt/β-catenin signalling in CRC are not yet clear.

In the present study, we found that JARID1B was elevated in CRC tissues compared with normal colonic tissues using quantitative reverse transcription (qRT)-PCR, western blot and immunohistochemistry. JARID1B expression was correlated with patient survival time. Furthermore, JARID1B promoted CRC cell proliferation in vivo and in vitro. In addition, our results further show that JARID1B regulates Wnt/β-catenin signalling to influence CRC cell proliferation. Additionally, we demonstrated that JARID1B significantly inhibited CDX2 expression in CRC, and CDX2 is crucial for JARID1B-mediated Wnt/β-catenin signalling in CRC. Finally, our study verified that JARID1B decreases CDX2 expression by demethylating H3K4me3. Therefore, our findings indicate that JARID1B is believed to be a promising target in the treatment of CRC.

Materials And Methods

Clinical samples
All the specimens of 54 patients from the Second Affiliated Hospital of Nanchang University were diagnosed as CRC by pathological test from June 2018 to December 2018. Total proteins and mRNAs from these patients’ clinical tissues were immediately obtained when tissues was still fresh. Moreover, formalin-fixed paraffin-embedded 130 CRC patients’ tissues from December 2012 to December 2017 were randomly selected to observe the expression levels by immunohistochemistry and their corresponding follow-up data about survival was obtained from the hospital database. Informed consent was obtained from all patients, those patients’ clinical data was recorded during hospitalization and the research program was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University.

**EDU assay**

According to what the manufacturer's protocol described, 20μM BrdU was put into CRC cells for 4h at 37°C. Then washed with PBS for three times, the cells were mixed with apollo reaction for 1h. The cells were stained with 100 μl of Hoechst 33342 (5 ug/ml) for 30 min to visualize the nuclei and observed under a fluorescence microscope (Olympus, Tokyo, Japan) [22].

**Real-time proliferation assay**

The xCELLigence real-time cell analysis (RTCA) system (ACEA Bioscience) was used to analyze cell proliferation. Cells were seeded on a 96-well plate (E-plate, Germany). After treated with different approaches for 12h, the growth rates were recorded every 10 min by the instrument. Under the same xCELLigence RTCA program, continue to monitor the changes of cell index for 36 hours. We used mean cell index values in real-time to present cell proliferation changes. For each experiment, we tested three biological replicates.

**In vivo tumorigenicity study**

After construction of a DLD-1 cell line that stably interfered with JARID1B expression, 5 × 10^6 cells in 200 μl of PBS were injected subcutaneously into the flanks of nude mice (male athymic BALB/c nude mice, 4-6 weeks). We used the random number table as a random method to determine the experimental animals, making sure more than 40 mice. Five mice were randomly selected every 5 days to get tumor tissues, and then tumor volumes were measured according to the protocol: V=1/2 (largest diameter)×(smallest diameter)^2. In vivo imaging showed tumor growth on day 30, and fluorescent pictures were taken. After 40 days, tumors tissues from 5 mice were harvested and individually weighed after the mice were anesthetized. The data was presented as tumor weight (mean ± SD).

**Cell culture**

Commercialized CRC cell lines SW620, HCT116, LOVO, SW480 and DLD-1 were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). SW620 and SW480 were cultured in L-15 medium (Gibco). LOVO was cultured in F12K medium (Gibco). DLD-1 and HCT116 were cultured in DMEM medium (Gibco). All cell lines were cultured at 37 °C, 5% CO₂ condition. Moreover, 10 uM XVA-939 from
American AbMole was used to inhibit β-catenin degradation. Over-expression plasmids and shRNA interference fragments are transfected into cells through lipofectamine 2000 and lipofectamine LTX (Catalog: 11668019, Invitrogen, Carlsbad, CA, USA).

Plasmids and reagents

SiRNA of JARID1B and CDX2 was synthesized by InvivoGen. The target sites of shRNA are detailed in Supplementary Table S1. The stable knockdown and overexpressed JARID1B CRC cells according to the Manufacturer's protocol. The shJARID1B and shCDX2 of CRC cells was selected based on resistance to hygromycin. The pcDNA3.1(+)-JARID1B-expressing CRC cells were selected using G418. The following reagents were used: Lipofectamine 3000 (Catalog: L3000001, Invitrogen, Carlsbad, CA, USA), dual-luciferase assay kit (Catalog: E1910, Promega), SimpleChipTM Enzymatic Chromatin IP KIT (Catalog: #9003, CST, USA), EdU kit (Catalog: C10310, RiboBio, China).

qRT-PCR, western blot analysis and co-immunoprecipitation (Co-IP)

qRT-PCR and western blot analysis were made as previously reported [23]. Whether it was tissue or cells, total RNA was extracted by Trizol reagent (Catalog: 15596026, Invitrogen, USA) and were quantified by SYBR Green assays with RT primers and SYBR Green from Takara Biotechnology (Catalog: DRR041A, TAKARA, Dalian, China). Human GAPDH was amplified in parallel as an internal control. For western blot, total proteins of clinical samples were obtained through RIPA lysis buffer and prepared cells were harvested by RIPA lysis buffer containing protease inhibitor cocktail (Catalog: P8340-1ML, Sigma-Aldrich). All the proteins were fractionated by 10% SDS-PAGE. The antibodies anti-JARID1B (Catalog: ab198884, 1:2000, abcam), anti-GSK-β (Catalog: ab93926, 1:1000, abcam), anti-Axin2 (Catalog: ab109307, 1:1000, abcam), anti-CDX2 (Catalog: ab76541, 1:1500, abcam), anti-c-MYC (Catalog: 10828-1-AP, 1:1000, proteintech), anti-phosphorylation-β-catenin (phospho Y142) (Catalog: ab27798, 1:2000, abcam), anti-β-catenin (Catalog: ab6302, 1:2000, abcam), anti-H3K4me3 (Catalog: ab8580, 1:1500, abcam), anti-Histone3 (Catalog: ab1791, 1:1500, abcam), anti-ubiquitin (Ub) (Catalog: ab7780, 1:500, abcam) and anti-tubulin (Catalog: 11224-1-AP, 1:1000, proteintech) were used. For co-immunoprecipitation, to deal with cells for 24 hours with 10 umol/L MG132, cell lysates were incubated overnight at 4 °C with anti-β-catenin, then conjugated to protein A/G agarose beads while rocking. Immunoprecipitates were washed with washing buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton-X), re-suspended in 2× loading buffer, and resolved by SDS-PAGE followed by immunoblotting analysis.

Gene set enrichment analysis (GSEA)

GSEA was a statistical analysis method for assessing whether a particular gene set showed statistically significant and consistent differences between two biological states, such as tumor and non-tumor or low-expression and high-expression groups [24]. Subsequently, mRNAs that were differentially expressed in CRC were imported into the GSEA software for Kyoto Encyclopedia of Genes and Genomes (KEGG) (http://www.kegg.jp) assessment. Results from the GSEA software were visualized by the GOplot R
software package. The GSEA software used a genome false discovery rate (FDR) of less than 25%, suggesting that FDR<25% indicated significantly enriched gene sets.

**Luciferase reporter assay**

Fragments of the CDX2 were amplified PCR using primers (Supplementary Table S2) and cloned into the luciferase reporter vector pGL3.0-Basic (Catalog: E1751, Promega, Madison, WI, USA) to generate CDX2 promoter reporter constructs. Plasmids containing firefly luciferase reporters and JARID1B plasmids were cotransfected into cells. For the TOP/FOP-Flash reporter assay [25], the TOP/FOP-Flash reporter and JARID1B plasmids were co-transfected into cells. After transfection for 48 h, the cells were harvested for analysis with the Dual-Luciferase Reporter Assay System (Catalog: E1910, Promega, Madison, WI, USA). Luciferase activity was measured using the PerkinElmer EnSpire Multilabel Reader 2300 (PerkinElmer Inc., Waltham, MA, USA). The luciferase intensity was normalized to the Renilla luciferase activity to normalize for transfection efficiency.

**Chromatin immunoprecipitation Assay (ChIP)**

ChIP assays were performed using the ChIP assay kit (Catalog: 8982, Cell Signaling Technology). Briefly, the cells were fixed with 1% formaldehyde for 10 minutes at room temperature, then washed with PBS for three times. After a series of processing according to the protocol, Digested DNA fragments was sonicated in the range of 150-300 bp. The immunoprecipitations were mixed with H3K4me3 antibody and agarose. The input and DNA were then subjected to qPCR.

**Statistical analysis**

Paired t test for the two groups and one-way ANOVA for more than two groups were used to analyze JARID1B expression data and its relationship with various clinicopathological factors. When data did not follow normal distribution, Mann-Whitney U test between two groups and Kruskal-Wallis H test for three or more groups should be used. Kaplan-Meier analysis and the logrank test were used for survival analysis. Correlation between two continuous values was analyzed by pearson's correlation. Furthermore, univariate and multivariate analyses were performed using the logistic regression model. All of the data were analyzed using GraphPad Prism and SPSS 22.0. p-values of <0.05 indicated statistically significant changes. Each experimental design included more than three biological repeats.

**Results**

**JARID1B was markedly upregulated in CRC tissues and was closely related to CRC progression.**

To investigate the role of JARID1B in the development of colorectal cancer, we investigated JARID1B expression levels in colorectal cancer, and 54 paired fresh CRC tissue samples and matched adjacent non-tumour tissues were used. qRT-PCR revealed that the mRNA expression level of JARID1B was notably elevated in CRC tissue samples compared with the corresponding adjacent tissues (Fig. 1a, b). Furthermore, western blotting showed that JARID1B protein expression in 54 paired CRC tissues was
consistent with the qRT-PCR results (Fig. 1c, d). Consistently, immunohistochemistry (IHC) results showed that JARID1B protein was highly expressed in 75.38% (98 of 130) of tissues, while weakly positive staining was observed in the adjacent non-tumour tissues (Fig. 1e). Then, we explored whether JARID1B expression affected clinicopathological parameters. As shown in Table 1, the high JARID1B expression group demonstrated a larger tumour size, higher CEA levels and greater T classification compared with the low JARID1B expression group. Furthermore, the Kaplan-Meier survival curves demonstrated that patients with high JARID1B expression levels in 130 immunohistochemical results had a significantly poorer overall survival than those with low expression levels (Fig. 1f), while univariate and multivariate analysis of overall survival in CRC patients also indicated that high JARID1B expression was a risk factor for 5-year survival (Table 2). Altogether, the findings demonstrated that JARID1B expression is upregulated in CRC and is implicated in the progression of CRC.

**JARID1B promoted the proliferation and tumorigenesis of CRC in vivo and in vitro.**

To investigate the potential biological function of JARID1B in CRC development, we initially examined JARID1B expression levels in CRC cells (SW620, HCT116, LOVO, SW480, DLD-1) and the non-malignant cell line (HCoEpic) by qRT-PCR and western blotting. The results showed that JARID1B expression was notably elevated in CRC cells (Fig. 2a, b). As shown in Table 1, the high JARID1B expression group demonstrated a larger tumour size, so we speculate that JARID1B may be functional in CRC proliferation. Next, we investigated the relationship between JARID1B expression and CRC cell proliferation. 5-ethynyl-20-deoxyuridine (EdU), colony formation and real-time cellular analysis (RTCA) assays revealed that the proliferation capacity of DLD-1 cells with short hairpin RNA (shRNA)-mediated JARID1B knockdown was markedly lower than that of the control group (Fig. 2c, d, e). In HCT116 where JARID1B was obviously increased as like DLD-1 cell lines, JARID1B knockdown also resulted in decreased cell proliferation (Supplementary Fig. 1). In contrast, JARID1B overexpression significantly enhanced the proliferation ability of LOVO cells (Supplementary Fig. 2). Furthermore, an in vivo experiment showed that the JARID1B knockdown group had smaller volumes and lower weights than the control group (Fig. 2f, g, h). That is, knockdown of JARID1B significantly inhibited tumour size and weight in vivo. These data demonstrated that JARID1B promotes CRC cell proliferation in vivo and in vitro.

**JARID1B influenced CRC proliferation by the Wnt/β-catenin signalling pathway.**

In subsequence, we explored the mechanism how JARID1B regulated CRC cell proliferation. Studies have indicated that the Wnt signalling pathway played an important role in CRC cells proliferation. Therefore, we speculated that JARID1B might regulate CRC cells proliferation by the Wnt/β-catenin signalling pathway. First, based on the TCGA COAD RNA expression dataset, Gene Set Enrichment Analysis (GSEA) revealed that JARID1B expression was positively correlated with Wnt signalling pathway (Fig. 3a). Second, we investigated the effect of JARID1B on the activation of the Wnt/β-catenin pathway in CRC cells. In DLD-1 cells with JARID1B knockdown, we observed that β-catenin, c-MYC and cyclin D1 were decreased (Fig. 3b). Knockdown of JARID1B significantly decreased total and nuclear β-catenin expression (Fig. 3c). Consistently, the TOP-Flash luciferase assay revealed that knockdown of JARID1B
inhibited Wnt/β-catenin pathway activity, proving that JARID1B played a key role in activation of the Wnt/β-catenin signalling pathway (Fig. 3d). In contrast, JARID1B over-expression significantly increased c-MYC, cyclin D1 and total/nuclear β-catenin in LOVO cells (Supplementary Fig. 3a, b, c). These results indicated that the Wnt/β-catenin signalling pathway was regulated by JARID1B.

Next, we would like to validate that cells proliferation mediated by JARID1B depended on the Wnt/β-catenin signalling pathway. Thus, we increased β-catenin expression in JARID1B-knockdown DLD-1 cells, showing that β-catenin over-expression significantly increased β-catenin, c-MYC and cyclin D1 in JARID1B-knockdown DLD-1 cells, demonstrating β-catenin could rescue the decreased Wnt/β-catenin pathway activity induced by knockdown of JARID1B (Fig. 3e, f). Moreover, β-catenin over-expression could rescue the proliferation ability of DLD-1 cells with knockdown of JARID1B in vivo and in vitro (Fig. 3g, h, i). Conversely, we suppressed β-catenin expression in JARID1B-overexpressing LOVO cells, showing that β-catenin knockdown inhibited β-catenin, c-MYC and cyclin D1 expression and decreased Wnt/β-catenin pathway activated by JARID1B over-expression (Supplementary Fig. 3d, e). The enhanced proliferation ability caused by JARID1B over-expression in LOVO cells was markedly decreased by the knockdown of β-catenin (Supplementary Fig. 3f, g). However, JARID1B regulated CRC proliferation by the Wnt/β-catenin pathway.

**JARID1B significantly inhibited CDX2 expression in CRC.**

We further explored how JARID1B regulated Wnt/β-catenin signalling in CRC cells. It has been reported that CDX2 knockdown promotes the proliferation of colorectal cancer cells via Wnt/β-catenin signalling. Thus, we speculated that JARID1B might regulate the expression of CDX2 to enhance the activity of Wnt/β-catenin signalling in CRC cells. Given the role of JARID1B in the epigenetic regulation of transcription, we first performed RNA-seq to identify potential JARID1B target genes involved in cell proliferation. The results showed that CDX2 was one of the most notably upregulated transcripts when JARID1B was knocked down (Fig. 4a). Next, qRT-PCR revealed that downregulation of JARID1B significantly increased CDX2 mRNA (Fig. 4b). Western blotting results showed that downregulation of JARID1B expression significantly increased the expression levels of CDX2, while the expression levels of β-catenin, c-MYC and cyclin D1 were decreased (Fig. 4c). Conversely, JARID1B overexpression decreased the levels of CDX2 mRNA expression (Fig. 4d). Western blotting results showed that upregulation of JARID1B expression significantly decreased the expression levels of CDX2, while the expression levels of β-catenin, c-MYC and cyclin D1 were increased (Fig. 4e). Furthermore, we examined CDX2 in 54 CRC tissue samples by western blotting and qRT-PCR. The results showed that the expression level of CDX2 was significantly higher in adjacent tissues than in tumour tissues (Fig. 4f, h). Finally, the statistical analysis results revealed that CDX2 expression was negatively correlated with JARID1B expression in CRC tissues (Fig. 4g, i). Consistently, Kaplan-Meier analysis indicated that patients with both high JARID1B expression and low CDX2 expression in 130 immunohistochemical results predicted the worst prognosis (Fig. 4i). Collectively, these data suggest that JARID1B negatively regulates CDX2 expression to increase Wnt/β-catenin signalling activity in CRC.
CDX2 was the key protein for JARID1B-mediated Wnt/β-catenin signalling in CRC cells.

To further validate whether JARID1B activated the Wnt/β-catenin signalling pathway by regulating CDX2 expression. After we first decreased the expression of CDX2 in JARID1B–knockdown DLD-1 cells, CDX2, GSK-3β, Axin2 and p-β-catenin, β-catenin, c-MYC and cyclin D1 expression levels were observed. The qRT-PCR results showed that knockdown of CDX2 inhibited the increase in CDX2 mRNA expression induced by JARID1B knockdown (Fig. 5a). Western blotting data showed that CDX2 knockdown decreased GSK-3β, Axin2 and p-β-catenin expression and markedly rescued the changes in β-catenin, c-MYC and cyclin D1 expression levels caused by JARID1B (Fig. 5b). Co-IP showed that JARID1B knockdown increased the ubiquitinated β-catenin level, which was rescued when CDX2 expression was knocked down (Fig. 5c). Simultaneously, the TOP-Flash luciferase assay revealed that the reduced Wnt/β-catenin signalling activity induced by JARID1B knockdown was partly abolished by the knockdown of CDX2 (Fig. 5d). In contrast, upregulation of CDX2 inhibited the JARID1B overexpression-induced increase in LOVO cells (Fig. 5e, f, g, h). These results demonstrated that CDX2 was required for the JARID1B-mediated Wnt/β-catenin signalling pathway in CRC cells.

JARID1B regulated CDX2 expression through demethylation of H3K4me3

We then explored how JARID1B regulated CDX2 expression at the transcriptional level. Studies have shown that JARID1B affects histone H3 lysine 4 (H3K4) demethylase and exhibits a strong transcriptional repression function. We explored whether JARID1B demethylates H3K4me3 at the promoter of CDX2 in CRC cells. We first decreased the expression of JARID1B and then observed the H3K4me3 protein expression levels and CDX2 promoter activity. Western blotting data showed that JARID1B knockdown markedly increased H3K4me3, CDX2, GSK-3β, Axin2 and p-β-catenin expression and decreased β-catenin, c-MYC and cyclin D1 expression (Fig. 6a). Simultaneously, a luciferase reporter gene assay showed that JARID1B downregulation increased CDX2 promoter activity (Fig. 6c). In contrast, overexpression of JARID1B decreased H3K4me3 protein expression and CDX2 promoter activity (Fig. 6b, c). In addition, we tested whether JARID1B expression was correlated with H3K4me3 modification at the CDX2 gene promoter in CRC cells. Moreover, the ChIP assay revealed that JARID1B knockdown increased H3K4me3 levels at CDX2 in DLD-1 cells (Fig. 6d), while overexpression of JARID1B decreased H3K4me3 levels at CDX2 in LOVO cells (Fig. 6d). Consistently, the ChIP qPCR assay revealed that JARID1B was recruited to CDX2 promoter, resulting in trimethylation of H3K4 in this region(Fig. 6e). After combining all the experimental results, we revealed a new important mechanism by which JARID1B regulated CDX2 expression through H3K4me3 to indirectly activate the Wnt/β-catenin pathway, leading to increased CRC proliferation (Fig. 6f).

Discussion

Tumour proliferation plays a crucial role in the development of CRC. Studies have confirmed that the proliferation of CRC cells is significantly correlated with the abnormal expression of histone demethylase. JARID1B plays an important role in cell fate decisions, cancer progression, and stem cell self-renewal[26,
Evidence is emerging that JARID1B contributes to the epigenetic plasticity that underlies malignant transformation[28]. Studies have also shown that JARID1B is overexpressed in numerous cancers[29], and JARID1B overexpression is associated with a poor prognosis in breast and prostate cancers[30, 31]. Studies have shown that the histone demethylase JARID1B is associated with CRC cell growth [32]. In this study, we explored the role of JARID1B in CRC proliferation. We found that JARID1B is significantly elevated in CRC, and overexpression of JARID1B protein expression resulted in significantly shorter overall survival. Furthermore, high JARID1B expression was closely associated with shorter overall survival in CRC patients. In addition, we provided evidence demonstrating that JARID1B promotes CRC cell proliferation in vivo and in vitro.

Next, we further explored the underlying mechanism by which JARID1B regulates CRC proliferation. The present studies have demonstrated that abnormal activation of the Wnt/β-catenin signalling pathway is an important cause of CRC[33]. Studies on the molecular mechanism of tumorigenesis and development related to the Wnt/β-catenin signalling pathway have always focused on four parts: receptors on the cell membrane, inhibitors or activators in the cytoplasm, transcription factors in the nucleus and downstream target genes of β-catenin[34]. In hypopharyngeal squamous cell carcinoma, JARID1B inhibits cell proliferation by activating β-catenin signalling[35]. Moreover, in hepatocellular carcinoma, basil polysaccharide was found to attenuate metastasis of rat hepatocellular carcinoma, simultaneously resulting in the downregulation of both JARID1B and β-catenin[36]. In line with these findings, we found a novel mechanism by which JARID1B regulates CRC proliferation via Wnt/β-catenin signalling. First, we found that the Wnt/β-catenin signalling pathway is the downstream pathway of JARID1B, and JARID1B levels were positively correlated with Wnt/β-catenin activity in CRC cells. Second, as JARID1B expression increased, the expression of β-catenin, c-MYC and cyclin D1 decreased, whereas JARID1B upregulation again had the opposite effect in CRC cells. Finally, β-catenin overexpression significantly inhibited the decrease in c-MYC and cyclin D1 expression in JARID1B–knockdown CRC cells and rescued the decreased Wnt/β-catenin pathway activity induced by downregulating JARID1B, rescued the proliferation ability in CRC cells with JARID1B downregulation in vivo and in vitro. In contrast, downregulation of β-catenin had the opposite results in JARID1B-overexpressing CRC cells. These results revealed a mechanism by which JARID1B contributes to CRC proliferation by activating the Wnt/β-catenin pathway.

Our current study also highlights the detailed mechanism by which the Wnt/β-catenin pathway is regulated by JARID1B in CRC cells. Caudal-type homeobox transcription factor 2 (CDX2), an essential intestine-specific regulator, is involved in the development and differentiation of intestinal epithelial cells and regulates the balance between cell proliferation and differentiation[37]. In the present study, many studies revealed that the CDX2 expression level was associated with CRC cell proliferation and poor prognosis for patients with CRC[38]. Recent evidence indicated that CDX2 inhibited the progression of CRC by suppressing the Wnt/β-catenin signalling pathway and transactivating GSK-3β and Axin2 expression[39]. Furthermore, CDX is a crucial member of the Wnt/β-catenin signalling pathway, and its expression is decreased in the liver metastasis of CRC[40]. Here, we revealed a novel mechanism by which JARID1B regulates the Wnt/β-catenin signalling pathway by inhibiting CDX2 expression. First, we found that CDX2 might be the most relevant gene in transcriptome sequencing technology of JARID1B-
downregulated CRC cells. We confirmed the negative correlation between JARID1B and CDX2 expression levels by cell experiments and detection of clinical tissues. Finally, we explored the mechanism by which JARID1B regulates CDX2 expression in CRC cells. A previous study showed that JARID1B enables H3K4me3 demethylation, and the depletion of JARID1B has been shown to specifically inhibit H3K4 demethylation and suppress CRC cell growth[32, 41]. Therefore, we proposed the underlying mechanism: JARID1B regulates CDX2 expression through H3K4me3. This conclusion was based on the following observations: on the one hand, JARID1B knockdown markedly increased H3K4me3 protein expression and CDX2 promoter activity; on the other hand, JARID1B overexpression decreased H3K4me3 levels and CDX2 promoter activity. However, future in-depth studies are needed to clarify whether other epigenetic players participate in the process and have similar underlying patterns.

Conclusions

In summary, our study demonstrated that JARID1B acted as an oncogene to promote the CRC progression. JARID1B inhibited CDX2 transcription level by demethylation of H3K4me3, which was effected at the CDX2 promoter region. Following CDX2 low expression, GSK-3β and Axin2 expression levels were decreased, and further phosphorylated β-catenin level was inhibited. So that less β-catenin was bound by ubiquitination to degrade, and more β-catenin was transported into the nucleus, which caused downstream target genes(c-MYC and cyclinD1) to be activated (Fig. 6e). Finally, CRC cells proliferation was accelerated. Our results uncovers the diverse role of JARID1B in cell biology and function of JARID1B in cancer development, which extends foundation for the development of new anti-cancer therapeutic strategies.

Declarations

Ethical Approval and Consent to participate

The inclusion of human participants, as well as the use of human data and human tissue in this study, was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University. The use of animals in this study was approved by the Animal Research Committee of the Second Affiliated Hospital of Nanchang University.

Consent for publication

All authors consent to publication.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional files.

Competing interests
The authors declare that they have no competing interests.

**Funding**

This study was supported by grants from the National Natural Science Foundation of China (no.81960521), the Project of the Jiangxi Provincial Department of science and technology (no.20171BAB215017) and the Project of Jiangxi Provincial Department of Education (no.2017GJJ170032).

**Author contributions**

Fanrong Liu conceived and designed the study. Da Huang, Fan Xiao, Haibin Hao, Fuzhou Hua, Zhenzhong Luo, Zhaoxia Huang, Qing Li, sha Chen, and Xiuzhi Cheng performed the experiments and collected data. Xinyue Zhang and Weilan Fang performed data analysis. All authors discussed and interpreted the data. Fanrong Liu and Xiaoyun Hu wrote the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**

We thank Nature Research English Language Editing service for editing the manuscript.

**Authors' information**

1 Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, China; 2 Department of Anesthesiology, Second Affiliated Hospital of Nanchang University, Nanchang, China; 3 Center for Education Evaluation, Nanchang Normal University, Nanchang, China; 4 Jiangxi Province Key Laboratory of Molecular Medicine, Nanchang, China; 5 Department of Pathology, Second Affiliated Hospital of Nanchang University, Nanchang, China; 6 These authors contributed equally to this work.

**Abbreviations**

JARID1B: Jumonji AT-rich interactive domain 1B; CRC: colorectal cancer; EdU: 5-ethynyl-20-deoxyuridine; RTCA: Real Time Cellular Analysis; ChIP: Chromatin immunoprecipitation Assay; GSEA: Gene Set Enrichment Analysis; H3K4: histone H3 lysine4; CDX2: Caudal-type homeobox transcription factor 2; qRT-PCR: quantitative reverse transcriptase PCR; Ub: ubiquitin; Co-IP: Co-immunoprecipitation; IHC: immunohistochemistry.

**References**

1. Nguyen LH, Goel A, Chung DC. Pathways of Colorectal Carcinogenesis. Gastroenterology. 2020;158: 291-302.

2. Inadomi J, Jung B. Colorectal Cancer-Recent Advances and Future Challenges. Gastroenterology. 2020; 158: 289-90.
3. Ansari KM, Arany PR, Eli A, et al. International conference on Cell Death in Cancer and Toxicology 2018 (CDCT-2018). Cell Commun Signal. 2018; 16: 34.

4. Bai Z, Tai Y, Li W, et al. Gankyrin activates IL-8 to promote hepatic metastasis of colorectal cancer. Cancer Res. 2013; 73: 4548-58.

5. Zhu G, Cheng Z, Huang Y, et al. MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NFkappaB/AP1 signaling pathway. Int J Mol Med. 2020; 45: 131-40.

6. Kuo KT, Huang WC, Bamodu OA, et al. Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor. Clin Epigenetics. 2018; 10: 107.

7. Kim J, Shin S, Subramaniam M, et al. Histone demethylase JARID1B/KDM5B is a corepressor of TIEG1/KLF10. Biochem Biophys Res Commun. 2010; 401: 412-6.

8. Harmeyer KM, Facompre ND, Herlyn M, et al. JARID1 Histone Demethylases: Emerging Targets in Cancer. Trends Cancer. 2017; 3: 713-25.

9. Li N, Dhar SS, Chen TY, et al. JARID1D is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis. Cancer Res. 2016; 76: 831-43.

10. Fork C, Gu L, Hitzel J, et al. Epigenetic Regulation of Angiogenesis by JARID1B-Induced Repression of HOXA5. Arterioscler Thromb Vasc Biol. 2015; 35: 1645-52.

11. Sun X, Li Z, Niu Y, et al. Jarid1b promotes epidermal differentiation by mediating the repression of Ship1 and activation of the AKT/Ovol1 pathway. Cell Prolif. 2019; 52: e12638.

12. Sun X, Li Z, Niu Y, et al. Jarid1b promotes epidermal differentiation by mediating the repression of Ship1 and activation of the AKT/Ovol1 pathway. Cell Prolif. 2019; 52: e12638.

13. Taylor-Papadimitriou J, Burchell J. JARID1/KDM5 demethylases as cancer targets? Expert Opin Ther Targets. 2017; 21: 5-7.

14. Kristensen LH, Nielsen AL, Helgstrand C, et al. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridinedicarboxylic acid as an in vitro and in cell inhibitor. FEBS J. 2012; 279: 1905-14.

15. Ohta K, Haraguchi N, Kano Y, et al. Depletion of JARID1B induces cellular senescence in human colorectal cancer. Int J Oncol. 2013; 42: 1212-8.

16. Ye C, Qi L, Li X, et al. Targeting the NAD+ salvage pathway suppresses APC mutation-driven colorectal cancer growth and Wnt/β-catenin signaling via increasing Axin level. Cell Commun Signal. 2020; 18: 16.

17. Cosin-Roger J, Ortiz-Masia MD, Barrachina MD. Macrophages as an Emerging Source of Wnt Ligands: Relevance in Mucosal Integrity. Front Immunol. 2019; 10: 2297.

18. Chen Y, Fang R, Yue C, et al. Wnt-Induced Stabilization of KDM4C Is Required for Wnt/beta-Catenin Target Gene Expression and Glioblastoma Tumorigenesis. Cancer Res. 2019. doi: 10.1158/0008-5472.CAN-19-1229.
19. Liu G, Liu S, Cao G, et al. SPAG5 contributes to the progression of gastric cancer by upregulation of Survivin depend on activating the wnt/beta-catenin pathway. Exp Cell Res. 2019; 379: 83-91.
20. Chen JF, Luo X, Xiang LS, et al. EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/beta-catenin signaling. Oncotarget. 2016; 7: 41540-58.
21. Hua F, Shang S, Yang YW, et al. TRIB3 Interacts With beta-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis. Gastroenterology. 2019; 156: 708-21.
22. Zhou CF, Wang M, Yang J, et al. Integral membrane protein 2A inhibits cell growth in human breast cancer via enhancing autophagy induction. Cell Commun Signal. 2019; 17: 105.
23. Huang D, Du X, Yuan R, et al. Rock2 promotes the invasion and metastasis of hepatocellular carcinoma by modifying MMP2 ubiquitination and degradation. Biochem Biophys Res Commun. 2014; 453:49-56.
24. Luo P, Zhang C, Liao FY, et al. Transcriptional Positive Cofactor 4 Promotes Breast Cancer Proliferation and Metastasis Through c-Myc Mediated Warburg Effect. Cell Commun Signal. 2019;17:36.
25. Liu S, Iaria J, Simpson RJ, et al. Ras enhances TGF-β signaling by decreasing cellular protein levels of its type II receptor negative regulator SPSB1. Cell Commun Signal. 2018; 16:10.
26. Shen W, Jin Z, Tong X, et al. TRIM14 promotes cell proliferation and inhibits apoptosis by suppressing PTEN in colorectal cancer. Cancer Manag Res. 2019; 11: 5725-35.
27. Gacek-Matthews A, Berger H, Sasaki T, et al. KdmB, a Jumonji Histone H3 Demethylase, Regulates Genome-Wide H3K4 Trimethylation and Is Required for Normal Induction of Secondary Metabolism in Aspergillus nidulans. PLoS Genet. 2016; 12: e1006222.
28. Harmeyer KM, Facompre ND, Herlyn M, et al. JARID1 Histone Demethylases: Emerging Targets in Cancer. Trends Cancer. 2017; 3: 713-25.
29. Catchpole S, Spencer-Dene B, Hall D, et al. PLU-1/JARID1B/KDM5B is required for embryonic survival and contributes to cell proliferation in the mammary gland and in ER+ breast cancer cells. Int J Oncol. 2011; 38: 1267-77.
30. Pippa S, Mannironi C, Licursi V, et al. Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B. Molecules. 2019; 24.
31. Lu W, Liu S, Li B, et al. SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination. Oncotarget. 2015; 6: 771-88.
32. Ohta K, Haraguchi N, Kano Y, et al. Depletion of JARID1B induces cellular senescence in human colorectal cancer. Int J Oncol. 2013; 42: 1212-8.
33. Wu S, Chen S, Lin N, et al. Long non-coding RNA SUMO1P3 promotes hepatocellular carcinoma progression through activating Wnt/beta-catenin signalling pathway by targeting miR-320a. J Cell Mol Med. 2020. doi: 10.1111/jcmm.14977.
34. Wang F, Zhu W, Yang R, et al. LncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer via activating the Wnt/beta-catenin pathway. Mol Cell Biochem. 2019; 456: 73-83.
35. Zhang J, An X, Han Y, et al. Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma. Cell Death Dis. 2016; 7: e2358.

36. Feng B, Zhu Y, Su Z, et al. Basil polysaccharide attenuates hepatocellular carcinoma metastasis in rat by suppressing H3K9me2 histone methylation under hepatic artery ligation-induced hypoxia. Int J Biol Macromol. 2018; 107: 2171-9.

37. Graule J, Uth K, Fischer E, et al. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway. Clin Epigenetics. 2018; 10: 120.

38. Bae JM, Lee TH, Cho NY, et al. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients. World J Gastroenterol. 2015; 21: 1457-67.

39. Yu J, Liu D, Sun X, et al. CDX2 inhibits the proliferation and tumor formation of colon cancer cells by suppressing Wnt/beta-catenin signaling via transactivation of GSK-3beta and Axin2 expression. Cell Death Dis. 2019; 10: 26.

40. Toth C, Sukosd F, Valicsek E, et al. Loss of CDX2 gene expression is associated with DNA repair proteins and is a crucial member of the Wnt signaling pathway in liver metastasis of colorectal cancer. Oncol Lett. 2018; 15: 3586-93.

41. Sun X, Li Z, Niu Y, et al. Jarid1b promotes epidermal differentiation by mediating the repression of Ship1 and activation of the AKT/Ovol1 pathway. Cell Prolif. 2019; 52: e12638.

Tables
Table 1
Relationship between JARID1B protein expression and clinicopathological features in CRC patients.

| Parameters                | Total 54\(^a\) | Relative JARID1B protein expression\(^b\) | \(p\) value |
|---------------------------|-----------------|------------------------------------------|-------------|
| Gender                    |                 |                                          | 0.53        |
| Male                      | 36              | 2.11 ± 0.85                               |             |
| Female                    | 18              | 2.34 ± 0.89                               |             |
| Age (years)               |                 |                                          | 0.71        |
| \(\leq 60\)               | 20              | 2.14 ± 0.93                               |             |
| \(> 60\)                  | 34              | 2.22 ± 0.83                               |             |
| Tumor size(cm)            |                 |                                          | 0.00**      |
| \(< 5\)                   | 23              | 1.61 ± 0.80                               |             |
| \(\geq 5\)                | 31              | 2.62 ± 0.62                               |             |
| Preoperative CEA level    |                 |                                          | 0.00**      |
| \(< 5\) ng/mL             | 40              | 1.86 ± 0.72                               |             |
| \(\geq 5\) ng/mL          | 15              | 3.13 ± 0.41                               |             |
| Histologic grade          |                 |                                          | 0.98        |
| well differentiated        | 42              | 2.17 ± 0.89                               |             |
| poorly differentiated      | 12              | 2.26 ± 0.80                               |             |
| T classification          |                 |                                          | 0.00**      |
| T1 + T2                   | 17              | 1.19 ± 0.54                               |             |
| T3 + T4                   | 37              | 2.65 ± 0.53                               |             |
| TNM stage                 |                 |                                          | 0.38        |
| I                         | 4               | 1.57 ± 0.55                               |             |
| II                        | 14              | 2.28 ± 1.02                               |             |
| III                       | 28              | 2.18 ± 0.88                               |             |
| IV                        | 8               | 2.37 ± 0.51                               |             |
| Lymphatic invasion        |                 |                                          | 0.52        |
| Negative                  | 21              | 2.12 ± 0.91                               |             |
| Positive                  | 33              | 2.24 ± 0.84                               |             |
| Distant metastasis        |                 |                                          | 0.88        |
| Negative                  | 45              | 2.16 ± 0.92                               |             |
| Positive                  | 9               | 2.33 ± 0.50                               |             |

\(^a\): 54 fresh tissue samples from June 2018 to December 2018, \(^b\): protein level in Tumor tissues/protein level in Adjacent tissues(mean ± SD), **\(p \leq 0.01\)
Table 2
Univariate and multivariate analysis of overall survival in CRC patients. (Cox proportional hazards regression model)

| Parameters (130 CRC patients) | Univariate analysis | Multivariate analysis |
|-------------------------------|---------------------|-----------------------|
|                               | HR  | 95%CI | p value  | HR  | 95%CI | p value  |
| Age (≦ 60/>60)                | 0.70 | 0.34–1.41 | 0.32  | 1.52 | 0.52–4.43 | 0.03*  |
| Gender (Male/Female)          | 1.13 | 0.57–2.22 | 0.73  | 1.65 | 0.62–4.38 | 0.01** |
| Histologic grade (well/poor) | 0.66 | 0.29–1.51 | 0.33  | 1.80 | 0.67–4.84 | 0.02*  |
| Tumor size (cm) (< 5/≧ 5)    | 1.78 | 0.90–3.51 | 0.10  | 2.12 | 1.13–3.98 | 0.02*  |
| CEA (ng/ml) (< 5/≧ 5)        | 1.09 | 0.75–1.60 | 0.64  | 2.53 | 1.50–4.27 | 0.00** |
| Lymphatic invasion (Positive/Negative) | 1.95 | 1.04–3.67 | 0.04* | 1.52 | 0.52–4.43 | 0.03*  |
| Distant metastasis (Positive/Negative) | 2.03 | 1.09–3.78 | 0.03* | 1.65 | 0.62–4.38 | 0.01** |
| T classification (T3 + T4/T1 + T2) | 2.65 | 1.20–5.85 | 0.02* | 1.80 | 0.67–4.84 | 0.02*  |
| TNM (III,IV/I,II)             | 2.49 | 1.24–5.00 | 0.01**| 2.12 | 1.13–3.98 | 0.02*  |
| JARID1B protein expression (High/Low) | 2.29 | 1.41–3.73 | 0.00**| 2.53 | 1.50–4.27 | 0.00** |

*a: Immunohistochemical results of 130 paraffin-embedded tissues from December 2012 to December 2017, *p ≤ 0.05, **p ≤ 0.01

Figures
Figure 1

JARID1B overexpression was associated with poor prognosis in patients with CRC. a Relative JARID1B mRNA expression levels in fresh 54 paired colorectal cancer and para-carcinoma tissues. b JARID1B expression was measured by qRT-PCR in tumor tissues and adjacent tissues. c Representative western blotting analysis of JARID1B protein expression (T, tumor tissues; A, adjacent tissues). d Quantification of JARID1B protein expression based on western blot analyses in fresh 54 paired CRC and adjacent non-tumor tissues. e Representative images and quantification of JARID1B staining in the paired CRC tissues.
Scale bar, 50 μm. Kaplan-Meier survival curves for 130 CRC patients showed JARID1B high expression had poor prognosis. *p<0.05, **p<0.01.
Downregulation of JARID1B expression led to decrease CRC proliferation in vitro and in vivo. a, b Western blot and qRT-PCR analysis of JARID1B protein expression in human nonmalignant cell line and CRC cell lines. c, d, e Cells proliferation capacities were detected by EdU, colony formation assay and RTCA assays in CRC DLD-1-cells transfected with the shJARID1B#1/#2 plasmid. f In-vivo tumor formation was examined by subcutaneously injecting CRC DLD-1-shNC (left) or CRC DLD-1-shJARID1B#1 (right) cells into the flanks of nude mice. Representative images obtained by an IVIS in-vivo imaging station after inoculation were shown. Corresponding tumor growth curves were obtained(g). h Tumor weight was counted at 40 days, JARID1B knockdown inhibited tumor proliferation.*p<0.05, **p<0.01.
Figure 3

Stable knockdown of JARID1B repressed CRC proliferation via Wnt/β-catenin signaling pathway. a Gene set enrichment analysis of JARID1B based on TCGA COAD RNA Seq dataset showed that JARID1B expression was positively correlated with Wnt/β-catenin signaling pathway. b Western blot detected JARID1B, β-catenin c-MYC and cyclinD1 expression in DLD-1 cells transfected with shNC or shJARID1B. c The total and nuclear protein levels of β-catenin were assessed by western blotting in DLD-1 cells transfected with shJARID1B or shNC. d The inhibitive effect of JARID1B downregulation on Wnt/β-catenin pathway was detected by TOP-Flash luciferase reporter assay. e Western blot analysis showed the effects on c-MYC, cyclinD1 expression in DLD-1 cells when both JARID1B silencing and β-catenin restoration. f TOP-Flash luciferase reporter assay showing that β-catenin overexpression rescued the decreased Wnt/β-catenin pathway activity of DLD-1-shJARID1B cells. g, h, i EdU and in-vivo tumor formation assays showed that over-expression of ectopic β-catenin significantly rescued cells proliferation in DLD-1- shJARID1B cells. *p<0.05.
Figure 4

JARID1B inhibited CDX2 expression in CRC cells. a The microarray profiling of gene expression in DLD-1-shJARID1B cells. b, c qRT-PCR and western blot detected CDX2, β-catenin, c-MYC, cyclinD1 expression in DLD-1 cells transfected with shNC or shJARID1B. d, e qRT-PCR and western blot detected CDX2 expression in LOVO cells transfected with vector or Flag-JARID1B. f, h Western blot analysis and qRT-PCR of CDX2 protein levels in CRC tissues and in paired adjacent tissues. g, i Scatter plots showed a negative correlation between JARID1B and CDX2 at the mRNA and protein levels in fresh 54 CRC samples. j
Kaplan-Meier analysis for 130 CRC patients follow-up data showed that the prognosis was the poorest for patients with both high JARID1B expression and low CDX2 expression. *p<0.05, **p<0.01.

**Figure 5**

CDX2 was required for JARID1B-mediated Wnt/β-catenin signaling in CRC cells. a mRNA levels of CDX2 were detected by qRT-PCR. The knockdown of CDX2 expression dramatically inhibits the increase of CDX2 expression in DLD-1-shJARID1B cells. b Western blot analysis showed that the knockdown of CDX2 expression markedly rescued the increase of GSK-3β, Axin2 and p-β-catenin expression and the decrease of β-catenin, c-MYC and cyclinD1 expression induced by JARID1B knockdown. c Ubiquitinated β-catenin levels when JARID1B and CDX2 knockdown in DLD-1 cells. d Silencing CDX2 attenuated the loss of downregulating JARID1B on Wnt/β-catenin as observed by TOP-Flash luciferase assay. e The upregulation of CDX2 mRNA expression markedly inhibited the decrease in CDX2 expression observed in JARID1B-overexpression LOVO cells. f Western blot analysis showed that the levels of JARID1B overexpression and CDX2 upregulation and their effects on GSK-3β, Axin2, β-catenin, c-MYC and cyclinD1 expression in LOVO cells. g Ubiquitinated β-catenin levels when JARID1B and CDX2 over-expressed in LOVO cells. h TOP-Flash luciferase reporter assay showed the overexpression of ectopic CDX2 attenuated the increase in Wnt/β-catenin activity in JARID1B-overexpression LOVO cells.*p<0.05.
Fig. 6

(a) Western blot analysis of various proteins in DLD-1 and LOVO cells with or without shNC, shJARID1B, or Flag-JARID1B treatment.

(b) Schematic representation of the promoters and CDX2 expression in DLD-1 and LOVO cells with or without Flag-JARID1B treatment.

(c) Relative luciferase activity in DLD-1 and LOVO cells with different treatments.

(d) Schematic representation of the relationship between JARID1B, H3K4me3, and the expression of CDX2.

(e) ChIP-qPCR analysis of H3K4me3 enrichment in DLD-1 and LOVO cells with different treatments.

(f) Diagram illustrating the localization of JARID1B, H3K4me3, and CDX2 in the nucleus and cytoplasm.
Figure 6

JARID1B demethylated H3K4me3 at the CDX2 promoter. a, b Western blot analysis was performed to detect the expression of CDX2, H3K4me3, Histone H3, GSK-3β, Axin2, p-β-catenin, β-catenin, c-MYC and cyclinD1 in DLD-1-shJARID1B and control DLD-1 cells, LOVO-JARID1B and control LOVO cells. c CDX2 promoter reporter luciferase assay using CRC cells transfected with the shJARID1B and shNC plasmid. Western blot was used to detect JARID1B, H3K4me3, CDX2, β-catenin and c-MYC expression in DLD-1 cells transfected with shNC or shJARID1B and in LOVO cells transfected with Vector or Flag-JARID1B. d Schematic representation of the CDX2 promoter and the two predicted H3K4me3 binding elements in the promoter region of the CDX2 gene. Quantitative chromatin immunoprecipitation (qChIP) assays were performed in shJARID1B, control DLD-1 cells, JARID1B-overexpression and control LOVO cells. e ChIP qPCR of recruitment of JARID1B to the CDX2 promoter region was normalized by input. f A model of mechanism underlying JARID1B-regulated CRC Cells proliferation by decreased of CDX2 and regulation of wnt/β-catenin signaling pathway. *p<0.05, **p<0.01, NS: no significant.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryFigureLegends.doc
- SupplementaryTable1.doc
- SupplementaryFigure2.tif
- supplementaryFigure1.tif
- SupplementaryFigure3.tif